Ranoluspec Gains EU Approval: Cost‑Effective Ranibizumab Biosimilar Launches November 2026
Ranoluspec, Sandoz’s new ranibizumab biosimilar, is EU‑approved and ready for launch in Nov 2026, offering comparable visual‑acuity results at 20‑30% lower cost.
4 minutes to read


